Symbol="GRCL"
AssetType="Common Stock"
Name="Gracell Biotechnologies Inc."
Description="Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China."
CIK="1826492"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="BUILDING 3, 418 GUILIN ROAD, XUHUI DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="223460000"
EBITDA="-576316032"
PERatio="None"
PEGRatio="None"
BookValue="16.68"
DividendPerShare="0"
DividendYield="0"
EPS="-1.14"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.239"
ReturnOnEquityTTM="-0.437"
RevenueTTM="0"
GrossProfitTTM="366000"
DilutedEPSTTM="-1.14"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="12.86"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="732.21"
PriceToBookRatio="0.792"
EVToRevenue="150.04"
EVToEBITDA="0.0518"
Beta="-1.442"
num_52WeekHigh="6.99"
num_52WeekLow="1.4"
num_50DayMovingAverage="4.186"
num_200DayMovingAverage="2.837"
SharesOutstanding="67715000"
DividendDate="None"
ExDividendDate="None"
symbol="GRCL"
open="3.30"
high="3.48"
low="3.03"
price="3.18"
volume="414637.00"
latest_trading_day="2023-08-21"
previous_close="3.32"
change="-0.14"
change_percent="-4.2169%"
aroon_positive_momentum_days="69"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="69"
Volume_recent_avg="256948"
Change_recent_avg="0.01"
Delta_recent_avg="0.36"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.19"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="69"
Aroon_momentum_negative="31"
image_negative_thumbnail_id_1="1122"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0155.jpeg"
image_negative_thumbnail_id_2="1103"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0136.jpeg"
image_neutral_thumbnail_id_1="557"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_neutral_thumbnail_id_2="536"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0063.jpeg"
image_positive_thumbnail_id_1="985"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0147.jpeg"
image_positive_thumbnail_id_2="677"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0031.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
